Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics won’t enroll more patients in the Phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, a test that was meant to act as confirmatory evidence for an approval in older boys. ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Friday 6 November →